JP2005515192A5 - - Google Patents

Download PDF

Info

Publication number
JP2005515192A5
JP2005515192A5 JP2003546928A JP2003546928A JP2005515192A5 JP 2005515192 A5 JP2005515192 A5 JP 2005515192A5 JP 2003546928 A JP2003546928 A JP 2003546928A JP 2003546928 A JP2003546928 A JP 2003546928A JP 2005515192 A5 JP2005515192 A5 JP 2005515192A5
Authority
JP
Japan
Prior art keywords
ecacc
ddm
cell line
melanoma cell
heterogeneous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003546928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005515192A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2002/000802 external-priority patent/WO2003045427A2/en
Publication of JP2005515192A publication Critical patent/JP2005515192A/ja
Publication of JP2005515192A5 publication Critical patent/JP2005515192A5/ja
Pending legal-status Critical Current

Links

JP2003546928A 2001-11-29 2002-11-29 ヒト又は動物において免疫応答を誘導するための医薬組成物 Pending JP2005515192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101770 2001-11-29
US33670601P 2001-12-07 2001-12-07
PCT/DK2002/000802 WO2003045427A2 (en) 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal

Publications (2)

Publication Number Publication Date
JP2005515192A JP2005515192A (ja) 2005-05-26
JP2005515192A5 true JP2005515192A5 (enExample) 2006-01-05

Family

ID=26069102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003546928A Pending JP2005515192A (ja) 2001-11-29 2002-11-29 ヒト又は動物において免疫応答を誘導するための医薬組成物

Country Status (11)

Country Link
US (2) US7771998B2 (enExample)
EP (1) EP1448229B1 (enExample)
JP (1) JP2005515192A (enExample)
AT (1) ATE446106T1 (enExample)
AU (1) AU2002365291B2 (enExample)
DE (1) DE60234115D1 (enExample)
DK (1) DK1448229T3 (enExample)
ES (1) ES2335396T3 (enExample)
IL (1) IL161832A0 (enExample)
RU (1) RU2313365C2 (enExample)
WO (1) WO2003045427A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
DE60316464T2 (de) * 2002-11-28 2008-06-26 Kufer, Peter, Dr. Neue real-time rt-pcr methode zur sensitiven detektierung mehrerer mage gen transkripte
KR100984602B1 (ko) * 2004-11-18 2010-09-30 고쿠리츠다이가쿠호진 히로시마다이가쿠 유전자 증폭에 의해 형성된 반복서열로부터, 발현이 억제된단백질을 발현시키는 방법, 키트, 및 형질전환체
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP1996614A1 (en) 2006-01-30 2008-12-03 The Ludwig Institute for Cancer Research Ctsp cancer-testis antigens
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
CA2687534A1 (en) * 2007-05-17 2008-11-27 Dnavec Corporation Method for production of dendritic cell
JP2011529080A (ja) * 2008-07-24 2011-12-01 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 癌幹細胞を標的とする治療法
JP2012504959A (ja) * 2008-10-08 2012-03-01 イントレキソン コーポレーション 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
JP2013527753A (ja) * 2010-03-23 2013-07-04 イントレキソン コーポレーション 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
GB201013443D0 (en) * 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
BR112014004779B1 (pt) 2011-08-30 2022-01-18 Astex Pharmaceuticals, Inc Formulações de derivados de decitabina, kit e processos relacionados
WO2013059778A2 (en) * 2011-10-20 2013-04-25 California Stem Cell, Inc. Antigen presenting cancer vaccine with gamma interferon
JP5871228B2 (ja) * 2011-10-31 2016-03-01 国立大学法人佐賀大学 慢性副鼻腔炎の検出方法
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP4089167A1 (en) 2012-02-09 2022-11-16 Baylor College of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2014007669A1 (ru) * 2012-07-04 2014-01-09 Volgushev Sergei Anatolievich Аутологичная клеточная вакцина для лечения онкологических заболеваний и способ ее получения
MX2018000016A (es) 2015-07-02 2019-01-31 Otsuka Pharma Co Ltd Composiciones farmaceuticas liofilizadas.
EP3350600A4 (en) 2015-09-18 2019-04-17 Baylor College of Medicine DISTINCTION OF AN IMMUNOGENIC ANTIGEN OF A PATHOGEN AND CORRELATION WITH CLINICAL EFFECTIVENESS
GB201520542D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.
BR112021000620A2 (pt) 2018-07-15 2021-04-20 Enochian BioPharma, Inc. métodos e composições com uso de células dendríticas recombinantes para terapia contra câncer
EP3903811A1 (en) 2020-05-01 2021-11-03 R.G.C.C. Holdings AG Pharmaceutical composition and method for inducing an immune response
EP3981425A1 (en) 2020-10-12 2022-04-13 R.G.C.C. Holdings AG Sars-cov-2 vaccines
CA3119597C (en) 2020-10-12 2023-07-11 R.G.C.C. Holdings AG Sars-cov-2 vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
EP1239866A4 (en) * 1999-12-10 2005-02-09 Epimmune Inc INDUCTION OF HER2 / NEU CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
WO2002072013A2 (en) 2001-03-09 2002-09-19 Baylor Research Institute Method of treating malignancies through induction of blood immune responses

Similar Documents

Publication Publication Date Title
JP2005515192A5 (enExample)
JP2020022459A5 (enExample)
JP2006526414A5 (enExample)
JP2007508573A5 (enExample)
ES2185560T3 (es) Sistema interactivo.
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
CA2185470A1 (en) Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
JP2011152135A5 (enExample)
JP2002538191A5 (enExample)
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
AU2003240631A8 (en) A t cell subpopulation regulating gut immunity
NO20033967L (no) Fremgangsmåte for fremstilling av mikropartikler som inneholder metoprolol
WO2004007528A3 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
WO2004070950A3 (en) Device for encoding a video data stream
WO2000001729A3 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
JP2007523200A5 (enExample)
CA2210294A1 (en) Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens
SE0302794D0 (sv) Novel microparticles for ultrasound contrast imaging and drug delivery
JP2000246178A5 (enExample)
WO2005108560A3 (en) Synthesis and purification of west nile virus virus-like particles
WO2007041397A3 (en) Targeted pharmaceuticals and ligands
Tamburini et al. Hurwitz groups and Hurwitz generation
NO941174L (no) Fremgangsmåte for opparbeiding av silisiumrike, uopplöste rester fra utluting av kobberholdige residuer fra organoklorsilansyntese
JP2003140040A5 (enExample)
Kelly et al. Exploring the relationship between economic development and underreported bleeding disorders